Skip to content

Prognosis of Isolated Left Ventricular Non-compaction in Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02885363
Acronym
NCVG
Enrollment
175
Registered
2016-08-31
Start date
2011-12-21
Completion date
2023-04-12
Last updated
2023-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Non Compaction

Brief summary

The main objective of this study is to clarify prospectively prognosis of patients newly diagnosed as carriers of a LVNC (incident cases) (i.e. without the occurrence of a survival of the following events: death, heart transplantation or hospitalization for cardiovascular complications). In a second time, prognosis factors will be identify in these patients with LVNC.

Detailed description

Isolated Left Ventricular Non Compaction (LVNC) is a rare cause of cardiomyopathy supposed to result from the cessation of normal embryogenesis infarction, and characterized by persistent ventricular trabeculations prominent. This is frequently a familial disease, but for which genetic characterization is still incomplete, and then requires the identification of new genes is desirable. The prognosis of LVNC is uncertain, with a mortality rate reported in the literature ranging from 2 to 38%. Some series conclude that LVNC is a very severe heart disease, responsible for a high mortality, other that LVNC is frequently associated with a favorable prognosis. These series are however limited by the short duration of follow-up and the small number of patients included. Between 2004 and 2006, a French registry LVNC, included 105 cases. It was found out that the LVNC was associated with a high rate of complications such as outbreaks of severe heart failure, need for heart transplantation, severe rhythm disorders, and embolic events. The prognosis of LVNC in France appears as pejorative: 1. \- there is no evidence that prognosis is different from other forms of cardiomyopathies. 2. \- the results of this register can be skewed by the inclusion of incident and prevalent cases (statistical survival bias). Thus, a longer-term monitoring and the identification of relevant prognostic markers are imperative to better understand this rare disease and to improve the therapeutic management.

Interventions

OTHERClinical examination
OTHERBlood sample
PROCEDUREEchocardiography

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged over 18 years * Presenting with Left Ventricular Non Compaction (LVNC, Group 1) or Idiopathic Dilated Cardiomyopathy (DCM, Group 2) * At distance of an acute heart failure thrust (\> 1 month) * Newly diagnosed (less than 6 months) * Diagnosis confirmed by echocardiography associated or not with a Magnetic Resonance Imaging (MRI) confirmed after central review * Having signed informed consent form

Exclusion criteria

* Age \<18 years * Patients who were diagnosed more than 6 months ago (prevalent cases) * Presence of an associated cardiac disease, including valvular, ischemic, or congenital disease * Refusal to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
Occurrence of death of cardiac originUp to 2 years
Occurrence of a cardiac transplantationUp to 2 years
Occurrence of hospitalization due to cardiac eventUp to 2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026